An industry perspective on the NIMH consensus statement on negative symptoms.
Negative symptoms of schizophrenia remain an area of substantial unmet clinical need. By convening a consensus conference in January 2005, the NIMH has taken a leading role in stimulating a resurgence of interest in methodological considerations related to development of new medications for treating negative symptoms. One audience for this work is clinical researchers in industry. They must take ideas, like those emerging from this consensus meeting, and determine whether they can be applied to their global trials in order to meet the needs of a broad group of customers, which include patients, clinicians, regulators, and payers. This article takes the ideas that surfaced from the NIMH consensus work and interprets them in terms of issues that industry faces for its clinical trials. Particular emphasis is given to addressing hurdles to study design and analysis that come when developing broad-spectrum or adjunctive agents that may be effective for negative symptoms.
Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. larry.alphs@pfizer.com
Larry
L
Alphs
D014150:Antipsychotic Agents / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004345:Drug Industry; D006801:Humans; D009315:National Institute of Mental Health (U.S.); D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D014481:United States
D014150:Antipsychotic Agents